04:53 PM EDT, 05/10/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said late Friday a phase 3 trial assessing Opdivo to potentially treat non-small cell lung cancer failed to reach its primary endpoint of progression-free survival.

The trial assessed Opdivo with concurrent chemoradiotherapy followed by Opdivo plus Yervoy versus concurrent chemoradiotherapy followed by durvalumab in people with the disease, the company said.

"Unfortunately, adding immunotherapy concurrently with definitive chemoradiation did not improve [progression-free survival] outcomes in this setting," Joseph Fiore, company vice president, global program lead, thoracic cancers, said in a statement.

Bristol-Myers Squibb ( BMY ) shares fell 0.8% in recent after-hours activity.

Price: 44.59, Change: -0.35, Percent Change: -0.78